83 Results for "

chimeric humanization

" in MedChemExpress (MCE) Product Catalog:
Products (83)

83 Results for "chimeric humanization" in MCE Product Catalog:

Cat. No.: HY-P99676
CAS No.: 2559704-24-2
Synonyms: SI-B001; BL-B01D1 Antibody

Target:  

EGFR

Research Areas:  

Cancer

Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P99868
CAS No.: 1831098-91-9
Synonyms: MGD 011

Target:  

CD19 CD3

Research Areas:  

Cancer

Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
loading...
    loading...
Cat. No.: HY-P99849
CAS No.: 1471999-69-5
Synonyms: ABT-806

Target:  

EGFR

Research Areas:  

Cancer

Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
loading...
    loading...
Cat. No.: HY-P99965
CAS No.: 1917321-26-6
Synonyms: SKY59; RO7112689; RG-6107
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
loading...
    loading...
Cat. No.: HY-P99896
CAS No.: 2361325-98-4
Synonyms: BTRC-4017A; RG-6194

Target:  

EGFR CD3

Research Areas:  

Cancer

Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P99488
CAS No.: 2574591-89-0
Synonyms: JSP-191; AMG-191

Target:  

c-Kit

Research Areas:  

Inflammation/Immunology Cancer

Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
loading...
    loading...
Cat. No.: HY-P99050
CAS No.: 2049079-64-1
Synonyms: BIVV009; IPN-009; TNT009

Target:  

Complement System

Research Areas:  

Endocrinology

Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
loading...
    loading...
Cat. No.: HY-P99422
CAS No.: 2247114-85-6
Synonyms: SHR-1316

Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
loading...
    loading...
Cat. No.: HY-P99481
CAS No.: 1608108-91-3
Synonyms: NEOD001

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
loading...
    loading...
Cat. No.: HY-P99489
CAS No.: 2098225-93-3
Synonyms: ABBV 181; PR 1648817

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
loading...
    loading...
Cat. No.: HY-P99708
CAS No.: 2412004-88-5
Synonyms: ABBV-151; ARGX-115

Target:  

TGF-beta/Smad

Research Areas:  

Cancer

Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
loading...
    loading...
Cat. No.: HY-P99834
CAS No.: 2611099-93-3
Synonyms: IAB22M2C; ImaginAb

Research Areas:  

Cancer

Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-P99166
CAS No.: 2329669-72-7
Synonyms: XMAB-20717

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
loading...
    loading...
Cat. No.: HY-P99430
CAS No.: 2296827-07-9
Synonyms: EM901; CC-93269

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P99614
CAS No.: 2517935-02-1
Synonyms: BFKB8488A; RG-7992; RO-7040551

Target:  

FGFR

Research Areas:  

Metabolic Disease

Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
loading...
    loading...
Cat. No.: HY-P99798
CAS No.: 2251756-52-0
Synonyms: AMG 420; BI-836909

Target:  

CD3

Research Areas:  

Cancer

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
loading...
    loading...
Cat. No.: HY-P99899
CAS No.: 2052591-32-7
Synonyms: PR-1498487

Target:  

ADC Antibodies

Research Areas:  

Cancer

Samrotamab (PR-1498487) is a humanized IgG1chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab can be used to synthesize antibody-drug conjugates (ADC). Samrotamab disrupts the LRRC15-SCG5 signaling module, binds to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, and binds to the lateral edge of the LRR solenoid while leaving the canonical concave β-sheet surface fully exposed. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration, and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research related to urothelial carcinoma, sarcoma, osteosarcoma, and undifferentiated pleomorphic sarcoma .
loading...
    loading...
Cat. No.: HY-P991200

Target:  

HCV Claudin

Research Areas:  

Infection

OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (Kd=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .
loading...
    loading...
Cat. No.: HY-P99169
CAS No.: 2378407-27-1
Synonyms: TJ004309

Target:  

CD73

Research Areas:  

Cancer

Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
loading...
    loading...
Cat. No.: HY-P99399
CAS No.: 2159141-27-0
Synonyms: RG 6100; RO7105705; MTAU-9937A

Target:  

Tau Protein

Research Areas:  

Neurological Disease

Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
loading...
    loading...